Preclinical validation of humanized chicken recombinant antibodies targeting GPCRs overexpressed in cancers

In recent years, significant scientific breakthroughs have opened the door to harnessing the immune system to fight cancer. For the first time in history, this brings a cure within reach. However, there are still some scientific and business hurdles to overcome, especially for a group of well-known proteins called G protein coupled receptors (GPCRs). GPCRs are difficult targets, and sometimes referred as intractable proteins, due to their membrane localization and the existence of several close analogues which often leads to non-specific mode of action of small molecules. Over the past 3 years, a multidisciplinary collaboration between researchers from Université de Sherbrooke (UdeS) and Immune Biosolutions (IBio) has tackled this problem and assembled a new therapeutic antibody discovery workflow. In this project, we propose to evaluate the therapeutic potential of two recombinant antibodies with antagonist properties targeting neurotensin receptor 1 and kinin B1 receptor for the treatment of several cancers.

Faculty Supervisor:

Fernand Gobeil;Fernand-Pierre Gendron;Philippe Sarret

Student:

Partner:

Immune Biosolutions Inc

Discipline:

Life Sciences

Sector:

Manufacturing; Professional, scientific and technical services

University:

Université de Sherbrooke

Program: